Loading...

We've got a brand new version of Simply Wall St! Try it out

CLS Holdings USA

CNSX:CLSH
Snowflake Description

Adequate balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CLSH
CNSX
$33M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

CLS Holdings USA, Inc. focuses on the extraction and conversion of cannabinoids in the United States. The last earnings update was 100 days ago. More info.


Add to Portfolio Compare Print
CLSH Share Price and Events
7 Day Returns
0%
CNSX:CLSH
-0.9%
CA Pharmaceuticals
0.1%
CA Market
1 Year Returns
-
CNSX:CLSH
-1.9%
CA Pharmaceuticals
-2%
CA Market
CLSH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
CLS Holdings USA (CLSH) 0% 0% 0% - - -
CA Pharmaceuticals -0.9% -10.9% -31.1% -1.9% 471% 399.4%
CA Market 0.1% -0.2% -2.3% -2% 8.2% 0%
1 Year Return vs Industry and Market
  • No trading data on CLSH.
  • No trading data on CLSH.
Price Volatility
CLSH
Industry
5yr Volatility vs Market

Value

 Is CLS Holdings USA undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of CLS Holdings USA to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for CLS Holdings USA.

CNSX:CLSH Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.9%
Perpetual Growth Rate 10-Year CA Government Bond Rate 1.9%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for CNSX:CLSH
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CA Govt Bond Rate 1.9%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.73
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.732 (1 + (1- 21%) (44.28%))
0.992
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.99
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.95% + (0.992 * 5.96%)
7.86%

Discounted Cash Flow Calculation for CNSX:CLSH using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for CLS Holdings USA is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

CNSX:CLSH DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.86%)
2020 18.50 Analyst x1 17.15
2021 28.65 Est @ 54.85% 24.62
2022 39.81 Est @ 38.98% 31.73
2023 50.91 Est @ 27.87% 37.61
2024 61.13 Est @ 20.09% 41.88
2025 70.09 Est @ 14.65% 44.51
2026 77.69 Est @ 10.84% 45.74
2027 84.03 Est @ 8.17% 45.87
2028 89.33 Est @ 6.3% 45.21
2029 93.79 Est @ 5% 44.01
Present value of next 10 years cash flows $378.34
CNSX:CLSH DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $93.79 × (1 + 1.95%) ÷ (7.86% – 1.95%)
$1,617.01
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,617.01 ÷ (1 + 7.86%)10
$758.74
CNSX:CLSH Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $378.34 + $758.74
$1,137.08
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,137.08 / 125.84
$9.04
CNSX:CLSH Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in CNSX:CLSH represents 1.15384x of OTCPK:CLSH
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.15384x
Value per Share
(Listing Adjusted, USD)
= Value per Share (USD) x Listing Adjustment Factor
= $ 9.04 x 1.15384
$10.43
Value per share (USD) From above. $10.43
Current discount Discount to share price of $0.30
= -1 x ($0.30 - $10.43) / $10.43
97.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price CLS Holdings USA is available for.
Intrinsic value
>50%
Share price is $0.3 vs Future cash flow value of $10.43
Current Discount Checks
For CLS Holdings USA to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • CLS Holdings USA's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • CLS Holdings USA's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for CLS Holdings USA's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are CLS Holdings USA's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:CLSH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-02-28) in USD $-0.34
OTCPK:CLSH Share Price ** OTCPK (2019-04-25) in USD $0.26
Canada Pharmaceuticals Industry PE Ratio Median Figure of 11 Publicly-Listed Pharmaceuticals Companies 18.87x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 15.61x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of CLS Holdings USA.

CNSX:CLSH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:CLSH Share Price ÷ EPS (both in USD)

= 0.26 ÷ -0.34

-0.77x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CLS Holdings USA is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • CLS Holdings USA is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does CLS Holdings USA's expected growth come at a high price?
Raw Data
CNSX:CLSH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.77x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.19x
Canada Market PEG Ratio Median Figure of 247 Publicly-Listed Companies 1.22x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for CLS Holdings USA, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on CLS Holdings USA's assets?
Raw Data
CNSX:CLSH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-02-28) in USD $0.25
OTCPK:CLSH Share Price * OTCPK (2019-04-25) in USD $0.26
Canada Pharmaceuticals Industry PB Ratio Median Figure of 145 Publicly-Listed Pharmaceuticals Companies 2.23x
Canada Market PB Ratio Median Figure of 2,446 Publicly-Listed Companies 1.46x
CNSX:CLSH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:CLSH Share Price ÷ Book Value per Share (both in USD)

= 0.26 ÷ 0.25

1.04x

* Primary Listing of CLS Holdings USA.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CLS Holdings USA is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess CLS Holdings USA's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. CLS Holdings USA has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is CLS Holdings USA expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
100.2%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is CLS Holdings USA expected to grow at an attractive rate?
  • Unable to compare CLS Holdings USA's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare CLS Holdings USA's earnings growth to the Canada market average as no estimate data is available.
  • CLS Holdings USA's revenue growth is expected to exceed the Canada market average.
Annual Growth Rates Comparison
Raw Data
CNSX:CLSH Future Growth Rates Data Sources
Data Point Source Value (per year)
CNSX:CLSH Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 100.2%
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 93.9%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 53.9%
Canada Market Earnings Growth Rate Market Cap Weighted Average 14.5%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:CLSH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:CLSH Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 148 1
2019-12-31 59 1
CNSX:CLSH Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-02-28 6 -10 -28
2018-11-30 3 -7 -26
2018-08-31 1 -5 -26
2018-05-31 -1 -10
2018-02-28 -1 -8
2017-11-30 -1 -6
2017-08-31 -1 -5
2017-05-31 -1 -5
2017-02-28 -1 -3
2016-11-30 -1 -3
2016-08-31 -1 -3
2016-05-31 -1 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if CLS Holdings USA is high growth as no earnings estimate data is available.
  • CLS Holdings USA's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:CLSH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from CLS Holdings USA Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:CLSH Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31
2019-12-31
CNSX:CLSH Past Financials Data
Date (Data in USD Millions) EPS *
2019-02-28 -0.34
2018-11-30 -0.41
2018-08-31 -0.53
2018-05-31 -0.24
2018-02-28 -0.26
2017-11-30 -0.23
2017-08-31 -0.20
2017-05-31 -0.23
2017-02-28 -0.14
2016-11-30 -0.16
2016-08-31 -0.14
2016-05-31 -0.13

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if CLS Holdings USA will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess CLS Holdings USA's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
CLS Holdings USA has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has CLS Holdings USA performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare CLS Holdings USA's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • CLS Holdings USA does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare CLS Holdings USA's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare CLS Holdings USA's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
CLS Holdings USA's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from CLS Holdings USA Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:CLSH Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-02-28 5.53 -28.17 8.99
2018-11-30 3.16 -25.84 20.38
2018-08-31 1.18 -25.67 4.71
2018-05-31 -9.58 3.12
2018-02-28 -8.34 2.36
2017-11-30 -6.22 1.39
2017-08-31 -4.82 1.49
2017-05-31 -4.87 1.61
2017-02-28 -2.87 1.67
2016-11-30 -3.34 2.18
2016-08-31 -2.75 2.31
2016-05-31 -2.61 2.27
2016-02-29 -2.72 2.53
2015-11-30 -2.20 2.12
2015-08-31 -1.87 1.82
2015-05-31 -1.52 1.50
2014-09-30 -0.32 0.24 0.08

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if CLS Holdings USA has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if CLS Holdings USA has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if CLS Holdings USA improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess CLS Holdings USA's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
CLS Holdings USA has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is CLS Holdings USA's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up CLS Holdings USA's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • CLS Holdings USA is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • CLS Holdings USA's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of CLS Holdings USA's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from CLS Holdings USA Company Filings, last reported 4 months ago.

CNSX:CLSH Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-02-28 31.49 14.49 11.97
2018-11-30 31.55 5.43 4.87
2018-08-31 28.89 4.15 5.95
2018-05-31 -0.63 0.47 0.05
2018-02-28 -1.30 1.43 0.02
2017-11-30 -1.89 0.93 0.26
2017-08-31 -2.10 1.05 0.01
2017-05-31 -1.89 1.14 0.08
2017-02-28 -3.07 2.17 0.01
2016-11-30 -2.92 1.77 0.03
2016-08-31 -2.05 1.22 0.00
2016-05-31 -1.43 0.44 0.09
2016-02-29 -1.06 0.51 0.03
2015-11-30 -1.42 0.98 0.02
2015-08-31 -1.01 0.77 0.06
2015-05-31 -0.59 0.62 0.21
2014-09-30 0.87 0.00 0.81
  • CLS Holdings USA's level of debt (46%) compared to net worth is high (greater than 40%).
  • Unable to establish if CLS Holdings USA's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • CLS Holdings USA has sufficient cash runway for 1.1 years based on current free cash flow.
  • CLS Holdings USA has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 82.3% each year.
X
Financial health checks
We assess CLS Holdings USA's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. CLS Holdings USA has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is CLS Holdings USA's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from CLS Holdings USA dividends.
If you bought $2,000 of CLS Holdings USA shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate CLS Holdings USA's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate CLS Holdings USA's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:CLSH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 337 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2.1%
Canada Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CNSX:CLSH Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as CLS Holdings USA has not reported any payouts.
  • Unable to verify if CLS Holdings USA's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of CLS Holdings USA's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as CLS Holdings USA has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess CLS Holdings USA's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can CLS Holdings USA afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. CLS Holdings USA has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of CLS Holdings USA's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jeff Binder
COMPENSATION $150,000
AGE 72
TENURE AS CEO 4.7 years
CEO Bio

Mr. Jeffrey I. Binder, also known as Jeff, has been the Chairman and Chief Executive Officer at CLS Holdings USA, Inc. since November 12, 2014. Mr. Binder served as President at CLS Holdings USA, Inc. since November 12, 2014. Mr. Binder served as Chief Financial Officer at CLS Holdings USA, Inc. Mr. Binder has invested in and mentored several start-up and mid-stage companies through his private holding company, JeMJ Financial Services, Inc., which he formed in 1988. Mr. Binder has been the Chairman of the Board and President of JeMJ Financial Services, Inc since 1988. Since 2008, Mr. Binder has been Founder, Chairman and President of Power 3 Network, Inc. He served as the Chairman of the Board, Chief Executive Officer and President at CLS Holdings USA, Inc., Prior to Reverse Merger with CLS Labs, Inc. (formerly, Adelt Design Inc.) since November 12, 2014. Mr. Binder was one of the individuals who founded CLS Labs in 2014. He served as the Chairman of Fearless International, Inc. and served as its Chief Executive Officer since July 14, 2006. Mr. Binder served as Manager of Fearless International, Inc. since July 14, 2006 and serves as its President. In 2003, Mr. Binder founded Infinity 8, Inc., where he served as its Chairman, Treasurer and a Director until 2011. Mr. Binder served as the Chief Executive Officer of Telmed Inc. until October, 1996. He has been Chairman of the Board of HP America, Inc., a privately traded holding company which owns health maintenance organizations and medical practice companies since 1995. He has been Chairman of Commodore Holdings Ltd since April, 1995. He has been Chairman of the Board of TelMed, Inc since 1991. Mr. Binder has been the Chairman of Infinity since January 2006. From August 2002 to August 2004, Mr. Binder served as the Chairman of Watermark International Productions. Mr. Binder served as Chairman of the Board of Tel-Med from 1991 to 1997. From September, 1985 to June, 1994, he served as Chairman of the Board of Georgetown Manor, Inc. (which formerly operated a retail furniture outlet) and Furniture Industries of Florida, Inc. He served as Vice Chairman, of GGL Industries, Inc., a private holding company. He serves as Director of Commodore Holdings Ltd. He served as a Director of Telmed Inc. since 1991. From November, 1994 to August, 1995, he served as a Director at NAL Financial Group, Inc. From December, 1987 to June, 1994, he served as a Director. Mr. Binder holds a Bachelor Degree from Drake University in 1968, a Master’s degree from the London School of Economics in 1969 and a Juris Doctor degree from George Washington National Law Center in 1971. He also served as a legislative assistant to Adlai Stevenson II, a United States Senator for Illinois, and practiced Law at Sonnenschein Nath & Rosenthal, LLP, Chicago and Illinois for five years.

CEO Compensation
  • Jeff's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Jeff's remuneration is higher than average for companies of similar size in Canada.
Management Team Tenure

Average tenure and age of the CLS Holdings USA management team in years:

1
Average Tenure
56
Average Age
  • The average tenure for the CLS Holdings USA management team is less than 2 years, this suggests a new team.
Management Team

Jeff Binder

TITLE
Chairman & CEO
COMPENSATION
$150K
AGE
72
TENURE
4.7 yrs

Andrew Glashow

TITLE
President
AGE
56
TENURE
0.3 yrs

Gregg Carlson

TITLE
Chief Financial Officer
AGE
62
TENURE
0.2 yrs

Don Decatur

TITLE
Chief Operating Officer of CLS Nevada
AGE
36
TENURE
1 yrs

Ben Sillitoe

TITLE
Chief Executive Officer of Oasis Cannabis
AGE
42
TENURE
1 yrs
Board of Directors Tenure

Average tenure and age of the CLS Holdings USA board of directors in years:

4.7
Average Tenure
56
Average Age
  • The tenure for the CLS Holdings USA board of directors is about average.
Board of Directors

Jeff Binder

TITLE
Chairman & CEO
COMPENSATION
$150K
AGE
72
TENURE
4.7 yrs

Andrew Glashow

TITLE
President
AGE
56
TENURE
1.6 yrs

Frank Koretsky

TITLE
Director
AGE
56
TENURE
5.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
08. Feb 19 Buy Navy Capital Green Management, LLC Company 10. Aug 18 02. Nov 18 12,500,000 $0.80 $7,500,000
08. Feb 19 Buy Navy Capital Green Management, LLC Company 06. Aug 18 06. Aug 18 13,750,000 $0.40 $5,500,000
X
Management checks
We assess CLS Holdings USA's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. CLS Holdings USA has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

CLS Holdings USA, Inc. focuses on the extraction and conversion of cannabinoids in the United States. The company extracts various cannabinoids from the marijuana plant and converts into concentrates, such as oils, waxes, edibles, and shatters. Its concentrates are used for electronic cigarettes vaporization, and pharmaceutical and other purposes. The company also offers consulting services to cannabis-related businesses comprising growers, dispensaries, and laboratories. CLS Holdings USA, Inc. was founded in 2014 and is headquartered in Las Vegas, Nevada.

Details
Name: CLS Holdings USA, Inc.
CLSH
Exchange: CNSX
Founded: 2014
$32,718,164
125,839,095
Website: http://www.clsholdingsinc.com
Address: CLS Holdings USA, Inc.
1810 E. Sahara Avenue,
Suite 613,
Las Vegas,
Nevada, 89104,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK CLSH New Common Stock Pink Sheets LLC US USD 03. Jun 2015
CNSX CLSH New Common Stock Canadian National Stock Exchange CA USD 03. Jun 2015
Number of employees
Current staff
Staff numbers
2
CLS Holdings USA employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/24 03:06
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/07/10
Last earnings filing: 2019/04/15
Last earnings reported: 2019/02/28
Last annual earnings reported: 2018/05/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.